Your browser doesn't support javascript.
loading
Multicenter Multireader Evaluation of an Artificial Intelligence-Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI.
Mehralivand, Sherif; Harmon, Stephanie A; Shih, Joanna H; Smith, Clayton P; Lay, Nathan; Argun, Burak; Bednarova, Sandra; Baroni, Ronaldo Hueb; Canda, Abdullah Erdem; Ercan, Karabekir; Girometti, Rossano; Karaarslan, Ercan; Kural, Ali Riza; Purysko, Andrei S; Rais-Bahrami, Soroush; Tonso, Victor Martins; Magi-Galluzzi, Cristina; Gordetsky, Jennifer B; Macarenco, Ricardo Silvestre E Silva; Merino, Maria J; Gumuskaya, Berrak; Saglican, Yesim; Sioletic, Stefano; Warren, Anne Y; Barrett, Tristan; Bittencourt, Leonardo; Coskun, Mehmet; Knauss, Chris; Law, Yan Mee; Malayeri, Ashkan A; Margolis, Daniel J; Marko, Jamie; Yakar, Derya; Wood, Bradford J; Pinto, Peter A; Choyke, Peter L; Summers, Ronald M; Turkbey, Baris.
Afiliación
  • Mehralivand S; Department of Urology and Pediatric Urology, University Medical Center, Mainz, Germany.
  • Harmon SA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Shih JH; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892-1088.
  • Smith CP; Clinical Research Directorate, Leidos Biomedical Research, Inc., Frederick, MD.
  • Lay N; Division of Cancer Treatment and Diagnosis: Biometric Research Program, National Cancer Institute, National Institutes of Health, Rockville, MD.
  • Argun B; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892-1088.
  • Bednarova S; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892-1088.
  • Baroni RH; Department of Urology, Acibadem University, Istanbul, Turkey.
  • Canda AE; Department of Radiology, University of Udine, Udine, Italy.
  • Ercan K; Diagnostic Imaging Department, Albert Einstein Hospital, Sao Paolo, Brazil.
  • Girometti R; Department of Urology, Koç University, School of Medicine, Istanbul, Turkey.
  • Karaarslan E; Department of Radiology, Ankara City Hospital, Ankara, Turkey.
  • Kural AR; Department of Radiology, University of Udine, Udine, Italy.
  • Purysko AS; Department of Radiology, Acibadem University, Istanbul, Turkey.
  • Rais-Bahrami S; Department of Urology, Acibadem University, Istanbul, Turkey.
  • Tonso VM; Department of Radiology, Cleveland Clinic, Cleveland, OH.
  • Magi-Galluzzi C; Department of Urology, University of Alabama at Birmingham, Birmingham, AL.
  • Gordetsky JB; Department of Radiology, University of Alabama at Birmingham, Birmingham, AL.
  • Macarenco RSES; O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL.
  • Merino MJ; Diagnostic Imaging Department, Albert Einstein Hospital, Sao Paolo, Brazil.
  • Gumuskaya B; Department of Pathology, Cleveland Clinic, Cleveland, OH.
  • Saglican Y; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL.
  • Sioletic S; Present address: Department of Pathology, Vanderbilt University, Nashville, TN.
  • Warren AY; Pathology Department, Albert Einstein Hospital, Sao Paolo, Brazil.
  • Barrett T; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Bittencourt L; Department of Pathology, Ankara Yildirim Beyazit University, School of Medicine, Ankara, Turkey.
  • Coskun M; Department of Pathology, Acibadem University, Istanbul, Turkey.
  • Knauss C; Department of Pathology, University of Udine, Udine, Italy.
  • Law YM; Department of Pathology, University of Cambridge, Cambridge, UK.
  • Malayeri AA; Department of Radiology, University of Cambridge, Cambridge, UK.
  • Margolis DJ; Department of Radiology, Federal Fluminense University, Rio de Janeiro, Brazil.
  • Marko J; DASA Company, Rio de Janeiro, Brazil.
  • Yakar D; Department of Radiology, University of Health Sciences Dr. Behçet Uz Child Disease and Pediatric Surgery Training and Research Hospital, Izmir, Turkey.
  • Wood BJ; Department of Radiology, Walter Reed Medical Center, Bethesda, MD.
  • Pinto PA; Department of Radiology, Singapore General Hospital, Singapore.
  • Choyke PL; Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD.
  • Summers RM; Weill Cornell Imaging, Cornell University, New York, NY.
  • Turkbey B; Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD.
AJR Am J Roentgenol ; 215(4): 903-912, 2020 10.
Article en En | MEDLINE | ID: mdl-32755355
ABSTRACT
OBJECTIVE. The purpose of this study was to evaluate in a multicenter dataset the performance of an artificial intelligence (AI) detection system with attention mapping compared with multiparametric MRI (mpMRI) interpretation in the detection of prostate cancer. MATERIALS AND METHODS. MRI examinations from five institutions were included in this study and were evaluated by nine readers. In the first round, readers evaluated mpMRI studies using the Prostate Imaging Reporting and Data System version 2. After 4 weeks, images were again presented to readers along with the AI-based detection system output. Readers accepted or rejected lesions within four AI-generated attention map boxes. Additional lesions outside of boxes were excluded from detection and categorization. The performances of readers using the mpMRI-only and AI-assisted approaches were compared. RESULTS. The study population included 152 case patients and 84 control patients with 274 pathologically proven cancer lesions. The lesion-based AUC was 74.9% for MRI and 77.5% for AI with no significant difference (p = 0.095). The sensitivity for overall detection of cancer lesions was higher for AI than for mpMRI but did not reach statistical significance (57.4% vs 53.6%, p = 0.073). However, for transition zone lesions, sensitivity was higher for AI than for MRI (61.8% vs 50.8%, p = 0.001). Reading time was longer for AI than for MRI (4.66 vs 4.03 minutes, p < 0.001). There was moderate interreader agreement for AI and MRI with no significant difference (58.7% vs 58.5%, p = 0.966). CONCLUSION. Overall sensitivity was only minimally improved by use of the AI system. Significant improvement was achieved, however, in the detection of transition zone lesions with use of the AI system at the cost of a mean of 40 seconds of additional reading time.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Inteligencia Artificial / Adenocarcinoma / Diagnóstico por Computador / Imágenes de Resonancia Magnética Multiparamétrica Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: AJR Am J Roentgenol Año: 2020 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Inteligencia Artificial / Adenocarcinoma / Diagnóstico por Computador / Imágenes de Resonancia Magnética Multiparamétrica Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: AJR Am J Roentgenol Año: 2020 Tipo del documento: Article País de afiliación: Alemania